Their patented CRISPR technology has the potential to edit DNA - "cutting" the harmful genes and "pasting" the healthy ones ...
|
|
Early investors in Amgen earned as much as 46,751% returns.
And we believe early investors in this biotech have the potential to do the same.
Their patented CRISPR technology has the potential to edit DNA - "cutting" the harmful genes and "pasting" the healthy ones.
It's been called a "once-in-a-generation" opportunity.
And as a dominant player, this firm controls the CRISPR patent other companies must license.
Their market potential is enormous.
Is this tiny company the next Amgen?
"The Buck Stops Here,"
Dylan Jovine, CEO & Founder
Behind the Markets
|
|
| | | Henry Smith, Editor of Earnings Policy
At times, our affiliate partners reach out to the Editors at Earnings Policy with special opportunities for our readers. The message above is one we think you should take a close, serious look at. |
|
|
|
|
| |
